Recordati : Maladies rares toujours en moteur de la croissance – Guidance 2024/2025 en ligne avec les attentes
>Baisse des charges non-récurrentes et de l’imposition bénéficient à la bottom-line - Recordati a publié hier en cours de séance ses chiffres au titre du T4 2023. Les ventes ressortent en croissance de 10.6% sur le trimestre à 526 M€ (-0.3% vs Css) malgré un impact forex négatif (-5.4% sur l’année) bénéficiant notamment de 1/ momentum positif de la franchise maladies rares (+11% au T4/+15% en lfl sur l’année à 715 M€) sous l’impulsion de l’activité oncologie et endoc...Recordati-Industria Chimica e Farmaceutica is a pharmaceutical group based in Italy. Co.'s operations are divided into two operating segments: pharmaceuticals (and pharmaceutical chemicals) and orphan drugs. Co.'s products include ZANIPRESS®/ZANEXTRA®/LERCAPREL®/LERCARIL®, an antihypertensive drug; ZANIDIP®/CORIFEO®/LERCADIP® (lercanidipine), an antihypertensive drug discovered and developed in Co.'s research laboratories; UROREC® (silodosin), a new drug indicated for the treatment of benign prostatic hyperplasia; and LIVAZO®/ALIPZA® (pitavastatin), a statin for the treatment of dyslipidemia, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.